Clinical Trial Update: Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating denosumab for bone loss associated with donor stem cell transplant, completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation Recipient
• Osteopenia
• Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia | Phase 2 | Status: COMPLETED | Results posted: 2024-03-13